Myoclonic epilepsy with ragged-red fibers (MERRF) syndrome was first described by Tsairis, et al. in 1973.^[@B1]^ The phenotypic spectrum broadened with the description of \> 320 MERRF-patients since then ([Table 1](#T1){ref-type="table"}).^[@B2]^ Here, we report further phenotypic variability.

The patient is a 71 years, HIV-negative, Caucasian female from nonconsanguineous parents, height 161 cm, weight 55 kg, with a history of a multiple organ disorder syndrome (MODS). Since early childhood she suffered from psoriasis. Since the age of 38 years recurrent diarrhea (1-2 times/day) developed. After a fall over a staircase at the age of 42 years she experienced a traumatic brain injury. Shortly after the trauma she developed left-sided peripheral facial palsy, which never resolved completely. In addition, mild but transient paraparesis of the lower limbs and stocking-type hypesthesia bilaterally were found. Since the age of 53 years bilateral progressive hypoacusis developed. At the age of 54 years diabetes was diagnosed. Since the age of 57 years she noticed myoclonic jerks which could be triggered by light, pain, touch, or fear. Myocloni were associated with recurrent falls (initially 3-4/month, at the age of 58 years 10-15/day) without losing consciousness. Wasting of the entire musculature shortly afterward resulted in weight loss of 10 kg in 1 year. She also reported blurred vision, recurrent double vision, and mild cognitive impairment (MCI) since the age of 57 years. Since the age of 62 years she required nocturnal noninvasive positive-pressure-ventilation and since the age of 65 years mechanical ventilation. Myoclonic seizures resolved only after application of piracetam at the age of 67 years. At the age of 69 years a tracheostoma was implanted. Her last medication included piracetam (24 g/day), glimepiride (1 mg/day), pantoprazole (40 mg/day), fluticasone (3 × 2 H), and bisoprolol (5 mg/day). The patient died at the age of 71 years from gastrointestinal bleeding after implantation of a percutaneous endoscopic gastrostomy. Her history was also positive for anemia, palpitations, hyperlipidemia, hypertension, early morning muscle cramps, easy fatigability, and multiple, large-scale, subcutaneous lipomas in the cervical, shoulder, and thoracic region. Her son had myoclonic epilepsy since the age of 12 years, hypoacusis, and experienced sudden death at the age of 17 years. The father's family had psoriasis. No information about her mother was available.

Clinical neurologic exam at the age of 58 years revealed left-sided ptosis, mild wasting of tongue edges, mild dysarthria, left-sided peripheral facial palsy, hypoacusis, weak head anteflexion (M5-), on the upper limbs right predominant diffuse weakness (M5-), diffuse wasting, reduced reflexes, bilateral dysdiadochokinesia, and on the lower limbs proximal weakness, diffuse wasting, absent reflexes, and recurrent myoclonic jerks. She was unable to stand or walk because of sudden loss of muscle tone during myocloni.

###### 

Phenotypic manifestations of the m.8344A \> G tRNA (Lys) mutation

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Manifestation**                                  **Current**\   **Previously**\                                 **References**
                                                     **patient**    **reported** [\*](#TFN1){ref-type="table-fn"}   
  -------------------------------------------------- -------------- ----------------------------------------------- ---------------------------------------------------------
  Myopathy                                           Yes            67                                              Catteruccia, et al.^[@B3]^

  Respiratory involvement                            Yes            67                                              Catteruccia, et al.^[@B3]^ and Blakely, et al.^[@B4]^

  Lactate acidosis                                   Yes            67                                              Catteruccia, et al.^[@B3]^ and Lorenzoni, et al.^[@B5]^

  Cardiac involvement                                Yes            53                                              Catteruccia, et al.^[@B3]^

  Polyneuropathy                                     Yes            47                                              Catteruccia, et al.^[@B3]^

  Myocloni                                           Yes            20-40                                           Catteruccia, et al.^[@B3]^

  Epilepsy                                           Yes            40                                              Catteruccia, et al.^[@B3]^

  Cerebellar ataxia                                  No             13-83                                           Catteruccia, et al.^[@B3]^ and Lorenzoni, et al.^[@B6]^

  Hypoacusis                                         Yes            25-35                                           Mancuso, et al.^[@B2]^

  Exercise intolerance                               Yes            15-25                                           Mancuso, et al.^[@B2]^

  Migraine                                           No             5-15                                            Mancuso, et al.^[@B2]^

  Elevated creatine-kinase                           Yes            UK                                              Chinnery, et al.^[@B7]^

  Elevated CSF protein                               No             2-8                                             DiMauro, et al.^[@B8]^

  Ptosis                                             Yes            UK                                              Blakely, et al.^[@B4]^

  Cognitive impairment                               Yes            UK                                              Mancuso, et al.^[@B2]^

  Multiple lipomatosis                               Yes            UK                                              Mancuso, et al.^[@B2]^

  Diabetes                                           Yes            UK                                              Mancuso, et al.^[@B2]^

  Myalgia                                            Yes            UK                                              Mancuso, et al.^[@B2]^

  Visual impairment                                  Yes            UK                                              Chen, et al.^[@B9]^

  Arterial hypertension                              Yes            UK                                              Austin, et al.^[@B10]^

  Arrhythmias                                        Yes            UK                                              Wahbi, et al.^[@B11]^

  Optic atrophy                                      Yes            UK                                              Mancuso, et al.^[@B2]^

  Short stature                                      Yes            UK                                              Lorenzoni, et al.^[@B6]^

  Tremor                                             No             UK                                              Mancuso, et al.^[@B2]^

  Leigh syndrome                                     No             UK                                              Scalais, et al.^[@B12]^ and Monden, et al.^[@B13]^

  Stroke-like episode/strokeno                       No             UK                                              Vastagh, et al.^[@B14]^ and Zaganas, et al.^[@B15]^

  Leukoencephalopathy                                No             UK                                              Biancheri, et al.^[@B16]^

  Depression                                         No             UK                                              Molnar, et al.^[@B17]^

  Fibrous bone dysplasia                             No             UK                                              Chen, et al.^[@B9]^

  Ophthalmoplegia                                    No             UK                                              Wiedemann, et al.^[@B18]^

  Parkinson syndrome                                 No             UK                                              Mancuso, et al.^[@B19]^ and Horvath, et al.^[@B20]^

  Pigmentary retinopathy                             No             UK                                              Lorenzoni, et al.^[@B6]^

  Chronic pancreatitis                               No             UK                                              Toyono, et al.^[@B21]^

  GI dysfunction[\*\*](#TFN2){ref-type="table-fn"}   Yes            UK                                              Tanji, et al.^[@B22]^

  Bulbar involvement                                 Yes            UK                                              NR

  Hyperlipidemia                                     Yes            UK                                              NR

  Psoriasis                                          Yes            UK                                              NR

  Diarrhea                                           Yes            UK                                              NR
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------

UK: Unknown; NR: Not reported; CSF: Cerebrospinal fluid; GI: Gastrointestinal

Figures are in percent and relate to the respective size of the cohort investigated,

Gastrointestinal dysfunction manifested as paralytic ileus.

![Left part: Myogenic needle electromyography (EMG) of the right anterior tibial muscle showing a pseudomyotonic discharge (upper panel), shortened motor unit action potentials (MUAP) with a mean of 7.9 ms (middle left), satellite potentials (middle right) and a dense, low-amplitude interference pattern (lower panel). Right part: Muscle biopsy from the left deltoid muscle revealed caliber changes and ragged-red fibers in hematoxylin and eosin staining (A), accompanied by cytochrome oxidase-negative fibers (B), Gomori trichrome staining revealed ragged-red fibers (C and D), which were visible in the succinate dehydrogenase enzyme histochemistry staining, (E) electron microscopy confirmed the SS accumulation of mitochondria showed concentrically arrayed tubular cristae and the presence of typical paracrystalline inclusions (F and G)](IJNL-16-45-g001){#F1}

Blood chemical investigations revealed elevated resting lactate of 2.8 mmol/L (n: \< 2.3 mmol/l), hyperlipidemia, fasting blood sugar of 157 mg/dl, and mild hyperCKemia of 113 U/l (n: \< 71 U/l). Lactate stress testing was highly abnormal (3.3, 3.6, 6.5, 8.9, 9.2 mmol/l). Nerve-conduction-studies at the age of 58 years revealed reduced nerve conduction velocity (left peroneal nerve). Needle-electromyography (EMG) of the right brachial-biceps-muscle was myogenic with numerous fibrillations and pseudomyotonic discharges, some satellite potentials, mean motor unit action potential (MUAP) duration of 11.4 ms, 15% polyphasia, and a dense, reduced interference-pattern. Needle-EMG of the right anterior-tibial-muscle was myogenic with 4/20 fibrillations, 2/20 pseudomyotonic discharges, a mean MUAP-duration of 7.9 ms, and a dense, low-amplitude interference pattern ([Figure 1](#F1){ref-type="fig"}). Visually-evoked potentials revealed a prolonged P100-latency bilaterally. Cerebral magnetic resonance imaging showed numerous lacunas in the basal ganglia and the left pedunculus cerebri, and mild diffuse atrophy. Electroencephalogram (EEG) at the age of 51 years revealed left predominant generalized spikes and short spike-wave complexes. EEG at the age of 56 years showed recurrently generalized spikes. EEG at the age of 57 years revealed occasional, paroxysmal activity over the frontal projections. Neuropsychological testing demonstrated MCI. Muscle biopsy from the left deltoid muscle at the age of 58 years revealed ragged-red fibers, increase of fat droplets in some fibers, ring-shaped hyperreactive subsarcolemmal (SS) in ragged-red fibers on staining for oxidative enzymes, and some cytochrome oxidase-negative fibers ([Figure 1](#F1){ref-type="fig"}). Electron microscopy showed SS accumulation of mitochondria, increased accumulation of free glycogen, subsarcolemmally and between myofibrils. The mitochondria showed concentrically arrayed tubular cristae and typical paracrystalline inclusions ([Figure 1](#F1){ref-type="fig"}). Genetic testing at the age of 59 years revealed the tRNA (transfer RNA) (Lys) mutation m.8344A \> G with a heteroplasmy rate of 70%.

The presented patient is interesting for the multiple organ nature of the phenotype, including the previously unreported phenotypic features psoriasis, chronic diarrhea, bulbar involvement, and hyperlipidemia. Phenotypic manifestations previously reported and present or absent in the presented patient are listed in [table 1](#T1){ref-type="table"}. Only for some of the previously reported phenotypic manifestations the frequency is known ([Table 1](#T1){ref-type="table"}).^23^ Her son had developed MERRF-syndrome as well and probably died from sudden cardiac death or sudden unexplained death in epilepsy.

Phenotypic features unreported so far in MERRF-syndrome were hyperlipidemia, psoriasis, bulbar involvement, and diarrhea ([Table 1](#T1){ref-type="table"}). Whether psoriasis should be regarded as a true manifestation of the disorder remains speculative since she might have inherited it from her father but the m.8344A \> G mutation cannot be excluded as cause of the dermatological abnormality. An argument for a causal relation is that dermatological abnormalities are a frequent feature of mitochondrial disorders (MIDs).^24^ Although there are some reports indicating that arterial hypertension could be associated with MID,^25,26^ this association is not generally accepted. Although many patients with MID also manifest with hyperlipidemia, it is not convincing to regard it as a manifestation of the underlying mutation in each case since today hyperlipidemia is endemic in the Western world. However, the high prevalence of hyperlipidemia in MID patients suggests that it can be a phenotypic feature. Bulbar involvement was mild but has not been previously reported in MERRF. An argument for bulbar involvement as a feature of MERRF is that it has been reported in other MID patients.^27^ Although diarrhea has not been reported as a phenotypic feature of MERRF, it is a common feature of other MIDs.^28^ The patient is also noteworthy for the late onset of the syndrome, which usually starts in childhood and rarely in adulthood. The commonly early onset is an argument for psoriasis to belong to the clinical spectrum of MERRF. It is also noteworthy that diarrhea was an early manifestation of the syndrome. The phenotypic variability could be explained with the variable heteroplasmy rates or other modifying factors.

This case shows that the phenotypic spectrum of MERRF syndrome is broader than previously reported and has to be classified as mitochondrial MODS. Diarrhea, psoriasis, bulbar involvement, and hyperlipidemia should be included in the phenotypic spectrum of MERRF-syndrome.

None.

Conflict of Interests
=====================

The authors declare no conflict of interest in this study.

Notes:
======

**How to cite this article:** Finsterer J, Kovacs GG. Psoriasis, bulbar involvement, and diarrhea in late myoclonic epilepsy with ragged-red fibers-syndrome due to the m.8344A \> G tRNA (Lys) mutation. Iran J Neurol 2017; 16(1): 45-9.
